{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"data_sharing_plan":["IPD Sharing (as of August 2016): Yes"],"condition":["Colorectal Neoplasm","Colorectal Neoplasms"],"disease":["Colorectal Neoplasm","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2222653"],"location":["China"],"study_start_month":["1"],"keyword":["Oxaliplatin"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer","description":"The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (SOX) and Oxaliplatin and Capecitabine (XELOX) in patients with peritoneal metastasis of colorectal cancer.","dates":{"creation":"2013-01-15"},"accession":"2222653","cross_references":{"ClinicalTrials___gov":["NCT02870153"]}}